49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

4 trials found

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05048238 (ClinicalTrials.gov)	September 30, 2022	31/8/2021	Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus	Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus (ALE11)	Systemic Lupus Erythematosus;Cutaneous Lupus	Drug: Tofacitinib	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Recruiting	18 Years	65 Years	All	10	Phase 1	United States
2	NCT03288324 (ClinicalTrials.gov)	August 23, 2017	29/8/2017	Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus	A 3-part Open-label Study Assessing Safety, Tolerability, Pharmacokinetic and -Dynamic Profiles, and ...	Cutaneous Lupus;Systemic Lupus Erythematosus	Drug: Tofacitinib	Children's Hospital Medical Center, Cincinnati	Pfizer	Completed	18 Years	45 Years	All	13	Phase 1/Phase 2	United States
3	NCT03159936 (ClinicalTrials.gov)	April 3, 2017	2/5/2017	Oral Tofacitinibin Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythema ...	Open Label Phase 2 Pilot Trial of Oral Tofacitinibin Adult Subjects With Discoid Lupus Erythematosus ...	Discoid Lupus Erythematosus;Systemic Lupus Erythematosus	Biological: Tofacitinib citrate	Tufts Medical Center	Pfizer	Recruiting	18 Years	65 Years	All	12	Early Phase 1	United States
4	NCT02535689 (ClinicalTrials.gov)	August 28, 2015	28/8/2015	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus; a Phase Ib C ...	Systemic Lupus Erythematosus	Drug: Tofacitinib;Drug: Placebo	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	Completed	18 Years	100 Years	All	34	Phase 1	United States

First Previous1Next Last